Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER)

Next Previous
Search
Trial Profile

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Atezolizumab (Primary) ; Everolimus (Primary) ; Giredestrant (Primary) ; Inavolisib (Primary) ; Ipatasertib (Primary) ; Palbociclib (Primary) ; Pertuzumab/trastuzumab (Primary) ; Ribociclib (Primary) ; Samuraciclib (Primary)
  • Indications Advanced breast cancer; HER2 positive breast cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms MORPHEUS BC
  • Sponsors Roche

    • Most Recent Events

    • 17 Feb 2025 Protocol was amended to increase the number of arms form 12 to 15, adding Palbociclib in one of the new treatment arm. The study will have flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the patient population.
    • 17 Feb 2025 Planned number of patients changed from 510 to 316.
    • 05 Feb 2025 Planned primary completion date changed from 30 Apr 2026 to 30 Nov 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top